Evidence ladder

GLP-1 Medicines Beyond Weight Loss: What Is Proven, Promising or Still Speculative?

Ozempic, Wegovy and Mounjaro are often discussed as weight-loss medicines. The real evidence is more nuanced: some benefits beyond weight are proven in specific groups, while others remain early science.

Élan Clinic · Educational article · Published June 15, 2026

GLP-1 based medicines are no longer just appetite medicines. In the right patient group, some have reduced heart events, slowed kidney disease, improved obesity-related heart-failure symptoms and reduced sleep-apnea severity. That does not mean they are universal heart, brain or longevity drugs.

The useful question is not whether these medicines are "good" or "bad." The useful question is: which effect is proven, in which patients, with which medicine, and how much of the benefit is likely to come from weight loss itself?

The short answer: cardiovascular and kidney outcome benefits are proven for selected GLP-1 medicines in defined high-risk groups. Sleep apnea, heart failure with preserved ejection fraction and fatty liver disease have strong clinical signals. Alzheimer’s disease, Parkinson’s disease, addiction and longevity remain research areas, not reasons to start treatment.

The evidence ladder

CategoryWhat belongs hereHow to interpret it
Proven in outcome trialsCardiovascular events in selected high-risk groups; kidney outcomes in type 2 diabetes with chronic kidney diseaseReal clinical outcome data, but not automatically generalisable to every weight-loss patient
Strong clinical signalObesity-related HFpEF symptoms, obstructive sleep apnea, MASH/fatty liver histologyUseful evidence, but often partly mediated by weight loss and fat distribution
Emerging or speculativeDementia, Alzheimer’s disease, Parkinson’s disease, addiction, cravings, longevityScientifically interesting, but not yet a clinical indication or promise

Proven: cardiovascular benefit in specific high-risk groups

The strongest evidence beyond weight loss is cardiovascular. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, but without diabetes. The trial included 17,604 participants and was published in the New England Journal of Medicine in 2023 (Lincoff AM et al.). The relative risk reduction was 20% for the composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

This is important because SELECT was not simply a diabetes trial. It showed cardiovascular benefit in people with overweight or obesity and existing cardiovascular disease even without diabetes. That makes it relevant to obesity medicine, not only diabetology.

Earlier cardiovascular outcome trials in type 2 diabetes also support cardiovascular outcome benefits for some GLP-1 receptor agonists: LEADER with liraglutide (Marso SP et al., NEJM, 2016, 9,340 patients), SUSTAIN-6 with semaglutide (Marso SP et al., NEJM, 2016, 3,297 patients), and REWIND with dulaglutide (Gerstein HC et al., Lancet, 2019, 9,901 patients).

Safe conclusion

Some GLP-1 medicines reduce cardiovascular events in defined high-risk populations. It is reasonable to say the benefit may not be explained by weight loss alone. It is not responsible to say these medicines protect the heart in everyone, or that the benefit is wholly separate from weight change.

Proven: kidney benefit in type 2 diabetes with chronic kidney disease

The FLOW trial tested semaglutide in people with type 2 diabetes and chronic kidney disease. It included 3,533 participants and was published in the New England Journal of Medicine in 2024 (Perkovic V et al.). Semaglutide reduced a composite outcome of major kidney disease events and cardiovascular death, slowed decline in estimated glomerular filtration rate, and reduced all-cause mortality compared with placebo.

This is a real outcome trial, not just a change in a laboratory marker. But the population matters. FLOW does not prove kidney protection for every person taking semaglutide for weight loss. It proves benefit in people with type 2 diabetes and chronic kidney disease.

Strong signal: heart failure with preserved ejection fraction

Obesity-related heart failure with preserved ejection fraction, often called HFpEF, is a condition where weight, inflammation, blood volume, visceral fat and impaired exercise capacity overlap. In STEP-HFpEF, semaglutide 2.4 mg improved symptoms, physical limitations, walking distance, inflammation markers and body weight in people with obesity-related HFpEF. The trial included 529 participants and was published in the New England Journal of Medicine in 2023 (Kosiborod MN et al.). A related trial in HFpEF with type 2 diabetes included 616 participants and was published in 2024.

This is clinically meaningful, but it is different from proving fewer deaths or fewer hospital admissions. It is best described as strong evidence for symptom and function improvement in a defined obesity-related HFpEF group.

Strong signal: sleep apnea

The SURMOUNT-OSA programme tested tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea. The two phase 3 trials included 469 participants and were published in the New England Journal of Medicine in 2024 (Malhotra A et al.). Tirzepatide reduced the apnea-hypopnea index, body weight, hypoxic burden, blood pressure, inflammation and patient-reported sleep impairment compared with placebo.

The most defensible mechanism is weight loss and fat-distribution change: less fat around the upper airway, less abdominal pressure, better breathing mechanics, and lower systemic inflammation. There may be additional effects, but the trials do not prove a separate direct sleep-apnea mechanism independent of weight loss.

Patients should not stop CPAP just because weight-loss treatment has started. Sleep apnea needs reassessment, often with repeat sleep testing, after substantial weight change.

Strong signal: fatty liver disease and MASH

Fatty liver disease is closely linked to visceral fat, insulin resistance and obesity. GLP-1 and GIP/GLP-1 medicines have shown promising liver results, especially for metabolic dysfunction-associated steatohepatitis, now often called MASH.

In a phase 2 trial of semaglutide in biopsy-confirmed NASH, 320 participants were studied (Newsome PN et al., NEJM, 2021). Semaglutide increased NASH resolution compared with placebo, although the main fibrosis endpoint was not significantly improved. In SYNERGY-NASH, tirzepatide improved MASH resolution and showed higher rates of fibrosis improvement in a phase 2 trial of 190 randomised participants (Loomba R et al., NEJM, 2024).

This is not a reason to describe GLP-1 medicines as a liver cure. It is a reason to say liver fat and metabolic liver disease are part of the same cardiometabolic picture that weight-management clinics should take seriously.

Emerging: Alzheimer’s disease and dementia

This is where public discussion often outruns the evidence. There are plausible reasons to study GLP-1 pathways in brain health: vascular risk, insulin signalling, inflammation and animal-model findings. Some observational analyses have raised a possible dementia signal, but this is not proof of prevention.

That distinction matters. People who receive one medicine rather than another often differ in age, health status, access to care, diabetes severity and many other factors. Large randomised trials of semaglutide in early Alzheimer’s disease, including EVOKE and EVOKE Plus, have been designed to answer this properly. Until those results are clear, GLP-1 medicines should not be presented as Alzheimer’s prevention or treatment.

Emerging: Parkinson’s disease

Some GLP-1 receptor agonists have been tested in Parkinson’s disease. A small trial of exenatide included 62 participants and was published in Lancet in 2017 (Athauda D et al.). A more recent trial of lixisenatide in early Parkinson’s disease included 156 participants and was published in the New England Journal of Medicine in 2024 (Meissner WG et al.). These studies are interesting, but they are not enough to treat GLP-1 medicines as Parkinson’s therapy in routine obesity care.

Emerging: addiction, alcohol and cravings

GLP-1 pathways interact with reward circuits, so research into alcohol use, nicotine and cravings is scientifically plausible. Early human evidence is mixed. A small phase 2 semaglutide trial in alcohol use disorder included 48 participants and was published in JAMA Psychiatry in 2025 (Hendershot CS et al.). It suggested reductions in some alcohol-related measures, but the study was small and not definitive. A trial of exenatide in alcohol use disorder included 127 participants and was published in JCI Insight in 2022 (Klausen MK et al.); results were mixed.

This area may become important. For now, it is not a reason to prescribe or take GLP-1 medicines for addiction outside standard indications, specialist care or a clinical trial.

What may be happening biologically?

Several mechanisms may explain why effects appear beyond simple weight loss:

The honest answer is that multiple pathways probably overlap. In practice, a patient does not need a single mechanism. They need a safe plan, a clear indication, monitoring, and a way to protect results over time.

Élan Clinic’s view

The evidence is strong enough to take GLP-1 and GIP/GLP-1 treatment seriously as cardiometabolic medicine, not just cosmetic weight loss. It is also not strong enough to market these medicines as brain-protective, anti-addiction or age-reversal treatment.

For patients, the useful approach is measured: treat obesity and metabolic risk where treatment is appropriate, monitor comorbidities, preserve muscle, plan for maintenance, and do not confuse early science with proven benefit.

If you are considering medical weight management, book a consultation with Élan Clinic. We assess weight, metabolic risk, medication suitability, side effects and long-term maintenance together, not as separate problems.

Sources and funding context

Many major drug trials are industry funded because manufacturers are usually responsible for licensing studies. That does not make the data useless, but it does mean claims should stay close to the trial design and population. Where the evidence is observational or early-stage, this article labels it as such.